ARA-290 5MG

ARA-290:

Chemical Name: Cibinetide
Chemical Formula: C99H155N27O19
Molecular Weight: 1880.48 Da (Daltons)

ARA-290, also known as Cibinetide, is a small peptide derived from erythropoietin (EPO), specifically designed to activate the innate repair receptor (IRR) without stimulating the erythropoietic activity of EPO. This selective targeting allows ARA-290 to promote tissue repair and reduce inflammation without the risk of increasing red blood cell production, which is a common side effect of EPO treatments. ARA-290 is being extensively researched for its potential to treat conditions related to chronic inflammation, neuropathic pain, and tissue injury.

Mechanism of Action

ARA-290 works by selectively binding to the innate repair receptor (IRR), a receptor that is activated during tissue damage or inflammation. Unlike erythropoietin, which activates both the erythropoietic and repair pathways, ARA-290 only engages the IRR. This specificity allows it to:

• Promote Tissue Repair: ARA-290 supports the regeneration of damaged tissues by activating the IRR, which enhances cellular repair mechanisms.
• Reduce Inflammation: By limiting pro-inflammatory cytokines, ARA-290 has shown promise in reducing chronic inflammation associated with various diseases.
• Alleviate Neuropathic Pain: Studies suggest that ARA-290 has a neuroprotective effect, reducing neuropathic pain by protecting and restoring damaged nerve fibers.

Top 7 Research Benefits of ARA-290

• Neuropathic Pain Relief: ARA-290 is being actively studied for its potential to alleviate chronic neuropathic pain, particularly in conditions such as small fiber neuropathy (SFN). Research indicates that ARA-290 may improve nerve function and reduce pain perception in these patients by promoting nerve regeneration.

• Tissue Regeneration: ARA-290’s role in tissue repair makes it a promising candidate in studies involving tissue injury, including muscle damage, cardiac injury, and even potential use in diabetic complications like wound healing.

• Anti-Inflammatory Properties: Research suggests that ARA-290 may help control excessive inflammation by modulating the immune response. This has applications in autoimmune diseases, chronic inflammatory conditions, and other immune-mediated disorders where inflammation plays a detrimental role.

• Potential in Diabetic Complications: ARA-290 is being explored for its potential to reduce complications associated with diabetes, particularly neuropathy and tissue damage due to poor circulation. Its ability to target the IRR without affecting red blood cell production makes it particularly appealing for these studies.

• Reduction of Sarcoidosis Symptoms: Preliminary studies on patients with sarcoidosis, an inflammatory disease that affects multiple organs, have shown that ARA-290 may reduce symptoms related to nerve damage and inflammation. This makes it a compound of interest in chronic inflammatory disease research.

• Cardioprotective Effects: By promoting tissue repair and reducing inflammation, ARA-290 has potential cardioprotective effects, particularly in research involving heart disease or ischemia-related injuries. Researchers are studying its ability to reduce damage following a cardiac event like a heart attack.

• Improved Wound Healing: The peptide’s ability to enhance tissue repair has sparked interest in studying its role in improving wound healing, especially in conditions that impair normal healing processes, such as diabetes and vascular diseases.

Dosing Information for Research Purposes

In research settings, ARA-290 is typically administered via subcutaneous or intravenous injection. The dosing is determined based on the condition being studied and the model used in the research.

• Typical Research Dosing:
  Doses of 0.03 mg/kg to 0.1 mg/kg have been explored in studies focused on tissue repair, inflammation, and neuropathic pain. Dosing protocols may vary based on the duration of the study and the condition being targeted.

Research Safety and Considerations

ARA-290 is generally well-tolerated in early research, but, as with any peptide, researchers should monitor for potential side effects.

• Potential Side Effects:
  While rare, side effects reported in early studies include mild injection site reactions, such as redness or swelling. Researchers should also monitor for any unexpected immune responses, given ARA-290’s role in modulating inflammation.
• Long-Term Effects:
  As research on ARA-290 continues, understanding the long-term effects of the peptide on tissue health and immune function will be critical, particularly when used in chronic conditions like neuropathic pain or inflammatory diseases.

Researchers are particularly interested in ARA-290’s selective activity on the IRR, as this could allow for repeated dosing without the risks associated with erythropoietic stimulation, such as elevated red blood cell production or increased blood viscosity.

Conclusion

ARA-290 is a unique peptide derived from erythropoietin that selectively activates the innate repair receptor, making it a valuable candidate for research into chronic inflammatory conditions, neuropathic pain, and tissue regeneration. By avoiding erythropoiesis while promoting tissue repair and reducing inflammation, ARA-290 offers a novel approach to managing diseases with a chronic inflammatory component and conditions where nerve damage is a concern.

Disclaimer: ARA-290 is intended for research purposes only and is not approved for human use outside of regulated research environments. All research involving ARA-290 must adhere to legal and ethical guidelines.